Every mass tort follows a pattern. Understanding the lifecycle, and where a tort sits within it, determines whether advertising investment produces 5x returns or losses.
The Six Phases
Phase 1: Triggering Event
Something creates legal viability:
Scientific triggers:
- FDA warning or safety alert
- Academic study linking product to harm
- Whistleblower revelations
- Media investigation
Legislative triggers:
- New law creating liability pathway (Camp Lejeune)
- Regulatory change
- Statute of limitations extension
Legal triggers:
- First significant verdict
- Class certification
- MDL formation
Examples:
- Camp Lejeune: Justice Act signed (August 2022)
- Roundup: $289M California verdict (August 2018)
- Hair Relaxer: NIH study published (October 2022)
Phase 2: Early Advertising
First movers test the waters:
- Small TV buys in targeted markets
- Digital campaigns to gauge response
- Call center volume assessment
- Legal theory development
Economics: Case acquisition $1,000-$2,500 Risk: High, litigation outcomes uncertain Competition: Low. Few players yet
Who enters: Sophisticated aggregators, well-funded specialists betting on validation.
Phase 3: Verdict Validation
Plaintiffs win key cases:
- Bellwether trials produce verdicts
- Settlement discussions begin
- Media coverage increases
- Public awareness grows
What happens to advertising:
- Spending increases 3-5x
- More players enter
- Acquisition costs begin rising
Roundup example:
- Pre-verdict (August 2018): 281 ads
- Post-verdict same month: +3,503 ads
- September 2018: 7,113 ads ($1.4M)
Phase 4: Spending Explosion
The gold rush:
- National TV saturation
- All major aggregators competing
- Acquisition costs peak
- Case inventory building at scale
Economics: Acquisition costs 2-5x early phase Risk: Moderate, validation proven, settlement timing unknown Competition: Intense
Camp Lejeune example:
- 2022 spending: $111M+ (TV alone)
- Case costs: $1,000 → $5,000+ in months
- Every legal advertiser in market
Phase 5: Settlement Framework
Settlement structures emerge:
- Defendant(s) announce settlement frameworks
- Case values become clearer
- Processing and payout begins
- Inventory value crystallizes
What happens to advertising:
- New case acquisition slows
- Focus shifts to processing existing inventory
- Some advertisers exit
- Residual campaigns for late filers
Phase 6: Moderation/Resolution
Wind-down:
- Major settlements paid
- Advertising returns to low levels
- Remaining cases processed
- Tort becomes “mature”
Examples: Roundup, Talc (settlement frameworks in place but not fully resolved)
Mature indefinitely: Mesothelioma (new diagnoses continue, advertising persists at steady level)
The Lifecycle in Practice
Camp Lejeune: Compressed Timeline
| Phase | Timing | What Happened |
|---|---|---|
| 1. Trigger | Aug 2022 | Justice Act signed |
| 2. Early | Aug 2022 | Immediate advertising surge |
| 3. Validation | Aug 2022 | Legislative pathway = built-in validation |
| 4. Explosion | Aug-Dec 2022 | $111M+ TV spend |
| 5. Framework | 2023-2024 | Navy ELCR process, federal litigation |
| 6. Moderation | 2024+ | Advertising declining |
Camp Lejeune was unique: the legislative trigger provided instant validation, compressing phases 1-3 into weeks.
Roundup: Classic Pattern
| Phase | Timing | What Happened |
|---|---|---|
| 1. Trigger | 2015+ | IARC classification, early lawsuits |
| 2. Early | 2017-2018 | Growing advertising, legal development |
| 3. Validation | Aug 2018 | $289M verdict |
| 4. Explosion | 2018-2019 | $18.3M peak month (Aug 2019) |
| 5. Framework | 2020+ | $10.9B settlement announced |
| 6. Moderation | 2021+ | Advertising tapering |
Roundup followed the textbook pattern over 4+ years.
Zantac: The Failure Case
| Phase | Timing | What Happened |
|---|---|---|
| 1. Trigger | 2019 | FDA alerts, contamination concerns |
| 2. Early | 2019-2020 | Significant advertising investment |
| 3. Validation | Never | Courts excluded expert testimony |
| , | 2022+ | Cases dismissed, advertising collapsed |
Lesson: Not every triggering event produces a viable tort. Zantac shows what happens when Phase 3 validation doesn’t occur, advertising investment is lost.
Reading the Lifecycle
Where Are Current Torts?
| Tort | Current Phase | Implication |
|---|---|---|
| Hair Relaxer | Phase 2/3 (Early validation) | Higher risk, better economics |
| PFAS/AFFF | Phase 4 (Growing) | Active opportunity, rising costs |
| NEC Formula | Phase 3/4 (Validation) | Bellwethers approaching |
| Paraquat | Phase 4/5 (Maturing) | Established but moderating |
| Camp Lejeune | Phase 5 (Framework) | Settlement clarity emerging |
| Roundup | Phase 5/6 (Mature) | Late-stage, tighter margins |
| Talc | Phase 5 (Complex) | Bankruptcy complications |
| Mesothelioma | Phase 6 (Perpetual) | Steady, mature |
| Tylenol | Phase 2? | Uncertain after adverse rulings |
Strategic Windows
Best economics (highest risk): Phase 2
- Acquisition: $1,000-$2,500/case
- Risk: Litigation may fail
- For: Sophisticated players with capital to risk
Best risk-adjusted (moderate risk): Phase 3-4
- Acquisition: $3,000-$6,000/case
- Risk: Validation proven, settlement timing unclear
- For: Most mass tort advertisers
Clearest economics (lowest returns): Phase 5-6
- Acquisition: $5,000-$10,000/case
- Risk: Lower, settlement frameworks known
- For: Conservative players wanting certainty
Timing Signals to Watch
Positive Signals (Tort Advancing)
- MDL formation or consolidation
- Bellwether trial scheduling
- Settlement discussions reported
- Defendant reserve increases
- Litigation funding interest
Negative Signals (Tort Stalling)
- Expert testimony challenges
- Daubert hearing losses
- Dismissal rulings
- Defendant bankruptcy maneuvers
- Scientific studies undermining causation
Red Flags (Exit Indicators)
- Court excludes plaintiff experts
- MDL dismissals
- Settlement talks collapse
- Key rulings against plaintiffs
- Advertising by competitors halting
For PI Firms: Lifecycle Awareness
Referral Timing
Understanding lifecycle helps evaluate referral decisions:
Early-phase torts: Higher referral fees possible (handling firms need inventory), but settlement timing uncertain.
Mature torts: Lower referral fees (more competition), but faster settlement and clearer outcomes.
Market Context
Mass tort advertising intensity affects your advertising costs:
- Phase 4 explosion: TV rates up, digital competition intense
- Phase 6 moderation: Some relief in advertising markets
Knowing which torts are in which phase helps anticipate competitive dynamics.
Opportunity Recognition
When clients mention exposures:
- Phase 1-2 torts: May be worth investigating, could become significant
- Phase 5-6 torts: Clear referral opportunity with known economics
- Failed torts (Zantac): Manage expectations, may have no viable path
The Perpetual Exception: Mesothelioma
Mesothelioma defies normal lifecycle:
- Triggering event: 1970s-1980s (asbestos litigation begins)
- Current phase: Perpetual Phase 6
Why it persists:
- 20-50 year latency period
- New diagnoses continue from past exposure
- Exceptional case values justify ongoing advertising
- Established infrastructure (trusts, specialists)
$580 million over a decade, not from explosions, but from consistency.